Anagenics Ltd logo

Anagenics Ltd(ASX) AN1

Market CapA$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-100%
5 Year-92%
1 Year+0%
1 Month-17%
A$0.01
+0.00%
+0.00Today
Anagenics Ltd last closing stock price
MetricPriceDate
Last closeAUD 0.012026-10-12
Anagenics Ltd stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-16.67%AUD 0.012026-10-05
1 month-16.67%AUD 0.012026-09-11
3 month-28.57%AUD 0.012026-07-08
Year to date+0%AUD 0.012025-12-31
1 year+0%AUD 0.012025-10-09
3 year-78.26%AUD 0.022023-10-12
5 year-92.06%AUD 0.062021-10-13
Since inception-99.86%AUD 3.562005-12-09

Anagenics Ltd Financials at a Glance

Market Cap

A$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$9.91M

Net Income (TTM)

-A$927.20K

EPS (TTM)

A$0.00

P/E Ratio

12.50

Dividend

A$0.00

Beta (Volatility)

0.05 (Low)

Price

A$0.01

Volume

0

Open

A$0.01

Previous Close

A$0.01

Daily Range

A$0.01 - A$0.01

52-Week Range

A$0.01 - A$0.01

Estimated Earnings Date

Mar 3, 2027

AN1 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Anagenics Ltd

Anagenics Limited is a health, wellness, and beauty company based in Sydney, Australia. The company specializes in developing, manufacturing, and marketing anti-aging hair care and skin care products, primarily under the évolis and Uspa brand names.

Products and Services
  • Anti-aging hair care products under the évolis brand
  • Skin, hair, and body care products under the Uspa brand
  • Distribution of wellness products to various retail channels
Growth Outlook
  • Recent quarterly revenue reached AUD 2.52 million, indicating strong market demand
  • Gross profit margin improved to 55.9% in the latest quarter
  • Current ratio of 5.27 suggests strong liquidity and financial health
Financial Highlights
  • Net income of AUD 181,787 reported for the latest quarter
  • Trailing twelve-month revenue of AUD 10.5 million reflects consistent growth
  • Operating income margin of 11.7% indicates effective cost management
Anagenics Limited operates in the consumer defensive sector, focusing on products that cater to health and beauty needs. The company has shown resilience in its financial performance, with a notable increase in revenue and gross profit margins. The strong liquidity position, as indicated by a current ratio of 5.27, provides a solid foundation for future growth. Recent quarterly results demonstrate a positive trend, with net income and operating income margins reflecting effective management strategies. The company's focus on anti-aging and wellness products positions it well within a growing market, appealing to consumers seeking quality health and beauty solutions.
AI Generated • Sep 17, 2026

Industry

Personal Products

CEO

Karen Anne Matthews

Headquarters

Sydney, NSW 2000, AU

AN1 Financials

Key Financial Metrics (TTM)

Gross Margin

54.54%

Operating Margin

12.21%

Net Income Margin

5.98%

Return on Equity

9.49%

Return on Capital

14.79%

Return on Assets

6.50%

Earnings Yield

8.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

985.45M

Volume

0

Avg. Volume

183.27K

Financials (TTM)

Gross Profit

A$4.85M

Operating Income

-A$689.76K

EBITDA

-A$178.71K

Operating Cash Flow

-A$2.65M

Capital Expenditure

-A$24.95K

Free Cash Flow

-A$2.67M

Cash & ST Invst.

A$577.43K

Total Debt

A$33.19K

Anagenics Ltd Performance Analysis

Anagenics Ltd annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 9,113,41431.2%
20242024-06-30AUD 10,803,16818.5%
20252025-06-30AUD 5,118,798-52.6%
20262026-06-30AUD 5,159,6790.8%
Anagenics Ltd sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-30-41.3%
Q42025-06-30-23.2%
Q22025-12-3127.8%
Q42026-06-30-4.2%
Anagenics Ltd annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-42.2%
20242024-06-30AUD -0.0288.0%
20252025-06-30AUD -0.00-86.2%
20262026-06-30AUD 0.00N/A
Anagenics Ltd sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3085.5%
Q42025-06-3070.0%
Q22025-12-31133.3%
Q42026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$2.52M

-44.8%

Gross Profit

A$1.41M

-3.9%

Gross Margin

55.93%

N/A

Market Cap

A$4.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$447.94K

N/A

Employees

11

N/A

Net Income

A$181.79K

+103.3%

EBITDA

A$387.75K

+118.6%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$577.43K

-64.4%

Total Debt

A$33.19K

-95.7%

Accounts Receivable

A$805.41K

+23.6%

Inventory

A$1.03M

-30.4%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$33.19K

-93.0%

Return on Assets

6.50%

N/A

Return on Invested Capital

14.90%

N/A

Free Cash Flow

-A$433.09K

+46.0%

Operating Cash Flow

-A$419.44K

+46.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SKN.AXSkin Elements Limited
A$0.00+0.00%
ASP.AXAspermont Limited
A$1.25+0.00%
ATX.AXAmplia Therapeutics Limited
A$0.10-9.09%
ATH.AXAlterity Therapeutics Limited
A$0.34-2.86%

Trending Stocks

Symbol / CompanyPricePrice Chg
KORUDirexion Shares ETF Trust - Direxion Daily Msci South Korea Bull 3x Shares
$15.74-11.82%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.19+8.14%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$128.40-8.13%
NOKNokia
$9.90-4.44%

Questions About AN1

What is the current price of Anagenics Ltd?

Anagenics Ltd is trading at A$0.01 per share.

What is the 52-week range for Anagenics Ltd?

Over the past 52 weeks, Anagenics Ltd has traded between A$0.01 and A$0.01.

How much debt does Anagenics Ltd have?

As of the most recent reporting period, Anagenics Ltd reported total debt of A$33.19K.

How much cash does Anagenics Ltd have on hand?

Anagenics Ltd reported A$577.43K in cash and cash equivalents in its most recent financial results.

What is Anagenics Ltd’s dividend yield?

Anagenics Ltd does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.